Jeffrey Stephens, MD
Infectious Disease · Macon, GANPI 1538239389
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $273,760 of the $356,216 with a category attached, or 76.9%. 18 manufacturers reported payments, led by Gilead at 51.4% of the total. Reporting peaked in 2019 at $113,963 and has fallen 80.3% since, to $22,467 in 2025. Among infectious disease clinicians in GA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 639 payments — averaging $557.46 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Gilead$183K
- Viiv Healthcare Company$77K
- Janssen Products, LP$66K
- Insmed, Inc.$20K
- Shionogi Inc$5K
- AbbVie$3K
- plus $2K from 12 others
Across 237 payments — averaging $2930.42 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Gilead$491K
- Viiv Healthcare Company$84K
- Janssen Research & Development, LLC$69K
- GSK$50K
What the payments were for
- Consulting fees$30,1058%
- Speaking & faculty fees$273,76077%
- Travel & lodging$39,37611%
- Food & beverage$12,5164%
- Education$4590%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Gilead | 258 | $183,228 |
| Viiv Healthcare Company | 99 | $76,998 |
| Janssen Products, LP | 62 | $66,218 |
| Insmed, Inc. | 53 | $19,529 |
| Shionogi Inc | 12 | $5,160 |
| AbbVie(2 entities) | 33 | $3,310 |
| Johnson & Johnson(2 entities) | 64 | $643 |
| Merck | 21 | $379 |
| Melinta Therapeutics, LLC | 15 | $339 |
| Theratechnologies Inc. | 6 | $96 |
| Cumberland Pharmaceuticals, Inc. | 4 | $84 |
| EMD Serono, Inc. | 4 | $69 |
| AstraZeneca | 2 | $68 |
| Tetraphase Pharmaceuticals, Inc. | 2 | $29 |
| La Jolla Pharmaceutical Company | 1 | $24 |
| Astellas Pharma US Inc | 1 | $15 |
| Paratek Pharmaceuticals, Inc. | 1 | $15 |
| Pfizer | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$356,216 in reported general payments places this provider in the 95th percentile of 260 infectious disease providers in Georgia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| BiktarvyBictegrav/Emtricit/Tenofov Ala | 808 | $3,271,632 |
| SymtuzaDarunavir/Cob/Emtri/Tenof Alaf | 249 | $1,196,587 |
| GenvoyaElviteg/Cob/Emtri/Tenof Alafen | 138 | $612,571 |
| TivicayDolutegravir Sodium | 150 | $404,703 |
| PrezcobixDarunavir/Cobicistat | 148 | $359,369 |
| DovatoDolutegravir Sodium/Lamivudine | 109 | $333,988 |
| CabenuvaCabotegravir/Rilpivirine | 36 | $244,810 |
| DescovyEmtricitabine/Tenofov Alafenam | 101 | $222,380 |
| JulucaDolutegravir/Rilpivirine | 62 | $219,535 |
| OdefseyEmtricitab/Rilpiviri/Tenof Ala | 49 | $182,405 |
| TriumeqAbacavir/Dolutegravir/Lamivudi | 36 | $161,734 |
| Etravirine | 51 | $56,486 |
| IsentressRaltegravir Potassium | 18 | $37,406 |
| Darunavir | 18 | $21,125 |
| Combivent RespimatIpratropium/Albuterol Sulfate | 36 | $18,628 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GileadBiktarvy, Genvoya, Descovy | $183,228 | $4,106,5821,047 claims |
| Viiv Healthcare CompanyTivicay, Dovato, Cabenuva, Juluca, Triumeq | $76,998 | $1,364,770393 claims |
| Janssen Products, LPSymtuza | $66,218 | $1,196,587249 claims |
| Johnson & JohnsonPrezcobix | $643 | $359,369148 claims |
| MerckIsentress | $379 | $37,40618 claims |
| PfizerEliquis | $13 | $6,79311 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 260 infectious disease providers in Georgia.
Other infectious disease in Macon
- Harold KatnerMacon$21K
- Quyen LuuMacon$12K
- Andrew DoldDacula$1.1M
- Zandraetta Tims-CookAtlanta$848K
- Jose VazquezAugusta$335K
- Larry AndersonAtlanta$300K
- Quintin RobinsonAtlanta$270K
- James McMillenAtlanta$177K
- Leandro MenaAtlanta$141K
- Cheryl NewmanAugusta$128K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.